Mesenchymal stem cell therapy - NextCell Pharma

Drug Profile

Mesenchymal stem cell therapy - NextCell Pharma

Alternative Names: ProTrans

Latest Information Update: 24 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator NextCell Pharma
  • Class Cell therapies; Stem cell therapies
  • Mechanism of Action Cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Type 1 diabetes mellitus
  • Research Renal transplant rejection

Most Recent Events

  • 12 Oct 2017 Phase-I/II clinical trials in Type-1 diabetes mellitus in Sweden (IV) (EudraCT2017-002766-50)
  • 05 Sep 2017 NextCell Pharma receives approval from ethics committee to initiate a phase I/II trial for Type-1diabetes mellitus
  • 24 Jul 2017 NextCell Pharma submits an IND application the Swedish Medical Products Agency for a phase I/II trial for Type-1 diabetes mellitus
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top